Literature DB >> 24013782

The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development.

Alexandra I Ziegler1, Melanie A Le Page, Mhairi J Maxwell, Jessica Stolp, Haoyao Guo, Abhirup Jayasimhan, Margaret L Hibbs, Pere Santamaria, Jacques F Miller, Magdalena Plebanski, Pablo A Silveira, Robyn M Slattery.   

Abstract

AIMS/HYPOTHESIS: Type 1 diabetes is characterised by early peri-islet insulitis and insulin autoantibodies, followed by invasive insulitis and beta cell destruction. The immunological events that precipitate invasive insulitis are not well understood. We tested the hypothesis that B cells in diabetes-prone NOD mice drive invasive insulitis through elevated expression of CD19 and consequent enhanced uptake and presentation of beta cell membrane-bound antigens to islet invasive T cells.
METHODS: CD19 expression and signalling pathways in B cells from NOD and control mice were compared. Expansion of CD8(+) T cells specific for insulin and islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) were compared in CD19-deficient and wild-type NOD mice and this was correlated with insulitis severity. The therapeutic potential of anti-CD19 treatment during the period of T cell activation was assessed for its ability to block invasive insulitis.
RESULTS: CD19 expression and signalling in B cells was increased in NOD mice. CD19 deficiency significantly diminished the expansion of CD8(+) T cells with specificity for the membrane-bound beta cell antigen, IGRP. Conversely the reduction in CD8(+) T cells with specificity for the soluble beta cell antigen, insulin, was relatively small and not significant. CONCLUSIONS/
INTERPRETATION: Elevated CD19 on NOD B cells promotes presentation of the membrane-bound antigen, IGRP, mediating the expansion of autoreactive T cells specific for antigens integral to beta cells, which are critical for invasive insulitis and diabetes. Downregulating the CD19 signalling pathway in insulin autoantibody-positive individuals before the development of type 1 diabetes may prevent expansion of islet-invasive T cells and preserve beta cell mass.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24013782     DOI: 10.1007/s00125-013-3038-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  50 in total

Review 1.  CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity.

Authors:  S Sato
Journal:  J Dermatol Sci       Date:  1999-12       Impact factor: 4.563

Review 2.  The who, how and where of antigen presentation to B cells.

Authors:  Facundo D Batista; Naomi E Harwood
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

3.  Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+ T-cells in T-cell receptor transgenic NOD mice.

Authors:  H S Jun; P Santamaria; H W Lim; M L Zhang; J W Yoon
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

4.  Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice.

Authors:  R C Rickert; K Rajewsky; J Roes
Journal:  Nature       Date:  1995-07-27       Impact factor: 49.962

5.  The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.

Authors:  Yasuhito Hamaguchi; Junji Uchida; Derek W Cain; Guglielmo M Venturi; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

6.  Cloning and characterization of the human and rat islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) genes.

Authors:  C C Martin; L J Bischof; B Bergman; L A Hornbuckle; C Hilliker; C Frigeri; D Wahl; C A Svitek; R Wong; J K Goldman; J K Oeser; F Leprêtre; P Froguel; R M O'Brien; J C Hutton
Journal:  J Biol Chem       Date:  2001-04-10       Impact factor: 5.157

7.  Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice.

Authors:  Siri Atma W Greeley; Makoto Katsumata; Liping Yu; George S Eisenbarth; Daniel J Moore; Heidi Goodarzi; Clyde F Barker; Ali Naji; Hooman Noorchashm
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

8.  Progression of autoimmune diabetes driven by avidity maturation of a T-cell population.

Authors:  A Amrani; J Verdaguer; P Serra; S Tafuro; R Tan; P Santamaria
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

9.  Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse.

Authors:  S Forsgren; A Andersson; V Hillörn; A Söderström; D Holmberg
Journal:  Scand J Immunol       Date:  1991-10       Impact factor: 3.487

10.  Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice.

Authors:  D Daniel; R G Gill; N Schloot; D Wegmann
Journal:  Eur J Immunol       Date:  1995-04       Impact factor: 5.532

View more
  4 in total

1.  CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy.

Authors:  P M Abraham; S H Quan; D Dukala; B Soliven
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

2.  CD19+CD24hiCD38hi regulatory B cells are associated with insulin resistance in type I Hashimoto's thyroiditis in Chinese females.

Authors:  Min Yang; Changji Du; Yinping Wang; Jun Liu
Journal:  Exp Ther Med       Date:  2017-08-14       Impact factor: 2.447

Review 3.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 4.  B cells and type 1 diabetes ...in mice and men.

Authors:  Rochelle M Hinman; Mia J Smith; John C Cambier
Journal:  Immunol Lett       Date:  2014-01-25       Impact factor: 3.685

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.